ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
9.61
+0.46 (5.03%)
At close: Oct 9, 2026, 4:00 PM EDT
9.64
+0.03 (0.31%)
After-hours: Oct 9, 2026, 7:30 PM EDT
ProMIS Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
11
Market Cap
86.18M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 63.82M |
| ImmuCell | 30.68M |
| NeurAxis | 5.32M |
| Equillium | 4.39M |
| Rallybio | 646.00K |
| Cardiff Oncology | 508.00K |
PMN News
- 5 days ago - ProMIS Neurosciences appoints Ivana Rubino as chief commercial officer - TheFly
- 5 days ago - ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer - GlobeNewsWire
- 26 days ago - ProMIS Neurosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 weeks ago - ProMIS Neurosciences Transcript: Moody Capital Disruptive Growth & Life Science Conference - Transcripts
- 4 weeks ago - ProMIS Neurosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 5 weeks ago - ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September - GlobeNewsWire
- 7 weeks ago - ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital - TheFly
- 1 month ago - ProMIS Neurosciences reports Q2 EPS ($1.28), consensus ($1.90) - TheFly